Oslo - Delayed Quote NOK
Zelluna ASA (ZLNA.OL)
17.00
+0.20
+(1.19%)
At close: 4:25:35 PM GMT+2
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in NOK.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Hans Vassgard Eid | Interim CEO & CFO | 3.15M | -- | -- |
Zelluna ASA
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 12
Description
As of March 3, 2025, Ultimovacs ASA acquired by Zelluna Immunotherapy AS. Ultimovacs ASA, a biotech company, develops immunotherapies against cancers in Norway. Its lead product candidate is UV1, a peptide-based therapeutic cancer vaccine that induces a specific T cell response against the pan-tumor antigen telomerase. Ultimovacs ASA was incorporated in 2011 and is headquartered in Oslo, Norway.
Corporate Governance
Zelluna ASA’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
May 8, 2025 at 12:00 PM UTC
Zelluna ASA Earnings Date
Recent Events
Recent Events Information Not Available
Related Tickers
HTD.MU Corcept Therapeutics Inc
56.94
+3.98%
GON.DU Geron Corp
1.2240
+7.18%
BT3.BE Lineage Cell Therapeutics Inc
0.3720
+10.71%
CANTA.ST Cantargia AB (publ)
1.5660
0.00%
RASP Actavia Life Sciences, Inc.
0.0040
0.00%
0M4.DU Mersana Therapeutics Inc
0.3381
+4.87%
PI3.DU Gubra AS
48.22
+4.64%
300759.SZ Pharmaron Beijing Co., Ltd.
22.72
+2.25%
PL3.F TuHURA Biosciences, Inc.
3.5800
+2.29%
50BA.F Bicycle Therapeutics plc
7.60
+16.92%